Pfizer’s 3Q Revenues up 31%

Pfizer 
3Q Revenues: $17.7 billion (+31%)
3Q Earnings: $4.5 billion (loss of $2.4 billion 3Q23)  
YTD Revenues: $45.9 billion (+2%)
YTD Earnings: $7.6 billion (+39%)
Comments: Growth in the quarter was driven by revenues of $854 million from legacy Seagen, which was acquired in December of 2023; Vyndaqel family sales, up 63% operationally; Eliquis, up 9% operationally, Xtandi, up 28% operationally; and Nurtec ODT/Vydura globally, up 45% operationally. Growth was partially offset by lower revenues for: Xeljanz, down 35% operationally; and Ibrance, down 12% operationally. Paxlovid revenue was $2.7 billion, compared to $202 million in 3Q23. Comirnaty revenues were $1.4 billion, up 9%. Pfizer CentreOne revenues were $285 million in the quarter, down 3%.